USP38 and neoplasm: Therefore, in different malignancies, we need to select appropriate inhibitors based on the characteristics of USP38 substrates and its specific regulatory mechanisms in the tumor, aiming to improve therapeutic response rates and safety while effectively minimizing off-target effects and drug resistance.